Study finds paxlovid treatment does not reduce risk of long COVID

A team of researchers from UC San Francisco has found that Paxlovid (Nirmatrelvir-ritonavir) did not reduce the risk of developing long COVID for vaccinated, non-hospitalized individuals during their first COVID-19 infection. They also found a higher proportion of individuals with acute symptoms rebound and test-positivity than previously reported. The study appears Jan. 4, 2024, in the Journal of Medical Virology. Paxlovid treatment […]

Paxlovid associated with lower risk of hospital admission

A Kaiser Permanente study confirms the benefit of nirmatrelvir-ritonavir, also known as Paxlovid, as an early-stage treatment to prevent hospitalization for people with mild to moderate COVID-19, regardless of prior immunity or age. The study was published March 15, 2023, in Lancet ID. “Among Kaiser Permanente members in Southern California who tested positive for coronavirus infection, receiving Paxlovid within 5 […]

Paxlovid effective in reducing COVID-19 hospitalization among vaccinated adults 50 and over

The antiviral drug nirmatrelvir plus ritonavir (Paxlovid) was granted Emergency Use Authorization for treating COVID-19 in December 2021. In clinical trials, the antiviral was associated with an 88% reduction in hospitalization or death among high-risk, unvaccinated individuals with COVID-19. However, little was known at the time about whether Paxlovid could significantly benefit vaccinated individuals, as well as individuals infected with […]

NMPA (China) approves Paxlovid conditionally to treat COVID-19 – Pfizer

China’s medical products regulator has given conditional approval for Pfizer’s COVID-19 drug Paxlovid, making it the first oral pill specifically developed to treat the disease cleared in the country. The National Medical Products Administration said Paxlovid is approved to treat adults who have mild to moderate COVID-19 and high risk of progressing to a severe condition. Further study on the […]